Abstract 1393TiP
Background
The standard 1L treatment (Tx) for patients (pts) with untreated mNSCLC is pembro + CT. However, there is an unmet need for novel Tx options, especially for pts with primary/secondary resistance to 1L SOC or poor response due to liver metastases (met). Livmo (ABBV-151), a first-in-class monoclonal antibody (mAb), targets the GARP-TGF-β1 complex, promoting immunoreactivity. The mAb budi (ABBV-181), binds to cell surface-expressed PD-1, resulting in checkpoint blockade. Livmo + budi has shown promising clinical activity in solid tumors. We describe a study to evaluate the combination of livmo and budi + CT vs pembro + CT in pts with mNSCLC.
Trial design
This multicenter phase 2/3 study (NCT06236438) will evaluate the optimal dose, safety, and efficacy of livmo and budi + CT vs pembro + CT in untreated mNSCLC. Eligible pts (≥18 years) have histologically/cytologically confirmed non-squamous mNSCLC with no known EGFR/ALK mutation or other targetable genomic aberration, ≥1 measurable lesion per RECIST v1.1, no prior Tx for mNSCLC, ECOG PS 0-2, and documented PD-L1 status. Stage 1 (phase 2, open label, ∼160 pts) comprises 4 parallel pt cohorts (randomized 1:1:1:1): livmo (dose A/B) and budi + CT, budi + CT, or pembro + CT. An initial safety lead-in for each cohort following a 6 + 3 design will be implemented. After the safety lead-in is completed and it is deemed safe to expand, additional pts will be enrolled into each cohort. The optimal livmo dose will be identified after all pts have enrolled and have ≥4 months follow-up. Stage 2 (phase 3, double-blind, ∼680 pts) includes 2 Tx arms (randomized 1:1): livmo (optimized dose) and budi + CT or placebo and pembro + CT. Pts receive Tx until a max of 35 cycles (1 cycle = 3 weeks) or meeting discontinuation criteria. Objectives and endpoints are in the table. Enrollment is ongoing in ∼200 sites globally. Table: 1393TiP
Objectives | Endpoints | |||
Primary | Secondary | Primary | Key secondary | |
Stage 1 | Safety/efficacy of livmo and budi + CTSelect RP3D livmo | Tolerability, immunogenicity, PK and efficacy of livmo and budi + CT | BOR (CR, PR by Inv) | PFS by invDOR invOS |
Stage 2 | Efficacy of RP3D livmo and budi + CT vs pembro + CT | Safety/tolerability and efficacy of livmo and budi + CT vs pembro + CTImpact of livmo and budi + CT on PROs | OS | PFS by BICRBOR (CR/PR by BICR)PROs |
RP3D, recommended phase III dose; BOR, best overall response; C/PR, complete/partial response; Inv, investigator; PFS, progression-free survival; DOR, duration of response; OS, overall survival; PRO, patient reported outcome; BICR, blinded central review
Clinical trial identification
NCT06236438.
Editorial acknowledgement
Medical writing support was provided by Delyth Eickermann, PhD, from Aptitude Health, The Hague, the Netherlands, and funded by AbbVie.
Legal entity responsible for the study
AbbVie.
Funding
AbbVie.
Disclosure
N. Girard: Financial Interests, Personal, Invited Speaker: AstraZeneca, BMS, MSD, Roche, Pfizer, Mirati, Amgen, Novartis, Sanofi, Gilead; Financial Interests, Personal, Advisory Board: AstraZeneca, BMS, MSD, Roche, Pfizer, Janssen, Boehringer, Novartis, Sanofi, AbbVie, Amgen, Lilly, Grunenthal, Takeda, Owkin, Leo Pharma, Daiichi Sankyo, Ipsen; Financial Interests, Institutional, Research Grant, Local: Roche, Sivan, Janssen; Financial Interests, Institutional, Funding: BMS, Leo Pharma; Financial Interests, Institutional, Research Grant: MSD; Other, Family member is an employee: AstraZeneca. A. Zer: Financial Interests, Personal, Invited Speaker: Roche, BMS, MSD, Takeda, Pfizer, Novartis; Financial Interests, Personal, Advisory Board: AstraZeneca, Steba, Oncohost; Financial Interests, Personal, Other, Safety Review Committee Member: Beyond Air; Financial Interests, Personal, Stocks/Shares: Nixio; Financial Interests, Institutional, Research Grant: BMS. L.E. Raez: Financial Interests, Personal and Institutional, Research Grant: AbbVie, Amgen, AstraZeneca, BMS, Daiichi Sankyo, Merck, Lilly Oncology, Loxo Pharmaceuticals, ONC4, Velos, Natera, Guardant, Bayer, TSCAN, TG therapeutics; Financial Interests, Personal, Speaker, Consultant, Advisor: Merck, BMS, Bayer, Daiichi Sankyo, Lilly Oncology, Loxo Pharmaceuticals. H. Horinouchi: Financial Interests, Personal, Invited Speaker: AstraZeneca, Eli Lilly, BMS/Ono, Merck Sharp & Dohme, Roche/Chugai, Novartis, Pfizer, Boehringer Ingelheim, Kyowa-Kirin, Nihon Kayaku, AbbVie; Financial Interests, Personal, Advisory Board: AstraZeneca, Eli Lilly, BMS/Ono, Merck Sharp & Dohme, Roche/Chugai, Amgen, Nihon Kayaku; Financial Interests, Personal, Steering Committee Member: Roche/Chugai; Financial Interests, Institutional, Research Grant: Roche/Chugai, Merck Sharp & Dohme, Daiichi Sankyo, Ono Pharmaceutical, AstraZeneca; Financial Interests, Institutional, Local PI: AbbVie. J. Zugazagoitia: Financial Interests, Personal, Invited Speaker: Takeda, BMS, AstraZeneca, NanoString, Guardant Health; Financial Interests, Personal, Advisory Board: Roche, Sanofi, BMS, Pfizer, Novartis, Janssen; Financial Interests, Personal and Institutional, Funding, Research Grant: AstraZeneca, Roche, BMS. X. Chen, S. Jha, C. Ferlini, D. Ngo: Financial Interests, Personal, Full or part-time Employment: AbbVie; Financial Interests, Personal, Stocks/Shares: AbbVie.
Resources from the same session
1352P - Real-world second-line outcomes of NSCLC patients receiving first-line chemotherapy plus immunotherapy
Presenter: Marco Russano
Session: Poster session 06
1353P - Efficacy and safety of docetaxel in combination with nintedanib or ramucirumab following immune checkpoint-Inhibitor treatment in patients with non-small cell lung cancer
Presenter: Konstantinos Ferentinos
Session: Poster session 06
1354P - Retrospective audit to determine the effect of antibiotic therapy on immune checkpoint inhibitor efficacy in stage IV NSCLC
Presenter: Deevyashali Parekh
Session: Poster session 06
1356P - Transcriptomic inflammatory profiling of non-small cell lung cancer: Insights from a 7-gene expression analysis
Presenter: Elba Marin
Session: Poster session 06
1357P - Multicenter phase II study of cisplatin and gemcitabine plus necitumumab in patients with unresectable, advanced lung squamous cell carcinoma who have progressed on or after initial treatment with immune checkpoint inhibitors plus platinum-based chemotherapy: WJOG14120L NESSIE study
Presenter: Hiroshige Yoshioka
Session: Poster session 06
1358P - Plinabulin/docetaxel versus docetaxel in survival benefits of 2L/3L EGFR wild-type NSCLC after platinum regimens (DUBLIN-3): A randomized phase III trial
Presenter: Trevor Feinstein
Session: Poster session 06
1359P - Lack of Abscopal effect and radiotherapy-induced lymphocyte depletion in advanced non-small cell lung cancer (NSCLC) patients treated with atezolizumab and radiotherapy
Presenter: Alexander Meisel
Session: Poster session 06
1361P - The Stereotactic Radiosurgery-Brain Prognostic Index (SRS-BPI): A novel prognostic index for lung cancer patients with brain metastases eligible for SRS
Presenter: Andreas Koulouris
Session: Poster session 06